MerTK genetic ablation or inhibition by small molecules in leukocytes decreases tumor growth and enhances anti-tumor immune response by switching myeloid cell cytokine production from an immunosuppressive to an inflammatory state in an immunocompetent mouse model of breast cancer (18, 19). This evidence concerns the gene MERTK and breast carcinoma.